Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Argent BioPharma Licences CannEpil Globally in US$5.5m Debt-Clearing Transaction
Argent BioPharma inks global CannEpil license with Splash Beverage, US$5.5m upfront debt-clearing, 15% royalty; boosts US growth and potential listing.
Latest Stories — SECTOR DESK
Optiscan Imaging Launches First Clinical Device into US Veterinary Market
Optiscan debuts InSpecta as its first US commercial clinical imaging device after FDA CVM submission, unlocking US sales in a $15.9B market.
Compumedics Delivers Record FY26 Revenue as SaaS Growth Accelerates
Compumedics posts FY26 revenue of $60.3m (+18%), SaaS up ~70% led by Somfit/Nexus 360; MEG delays temper guidance, FY27 targets double-digit growth.
Orthocell Appoints MediTime as Thai Distributor for Remplir Nerve Repair
Orthocell names MediTime exclusive Thai distributor for Remplir nerve repair, taps US$84m market; Thai FDA CY25 approval; $48m cash, no debt.
Imricor Medical Systems Gains FDA Paediatric Clearances for NorthStar and Diagnostic Catheter
Imricor gains FDA paediatric clearance for NorthStar and Vision-MR, unlocking radiation-free iMR procedures for children across 250+ US hospitals.
Imugene Adds Second Complete Response in Azer-Cel BTKi Cohort
Imugene logs a second complete response within 24 hours in Azer-cel BTKi cohort, Day-28 CR in MCL after BTKi failure, following FL CR.
Biome Australia Reports Record $23.9m Sales Revenue for FY26
Biome Australia posts record FY26 revenue of $23.9m, up 30%, led by Activated Probiotics; onshore manufacturing deal boosts 2027 outlook.
INOVIQ to Rework EXO-OC Study Path after Sample Quality Setback
INOVIQ retools EXO-OC path after sample quality setback; expanded retrospective data invalid, shifting to single-site/prospective validation.
Saluda Medical Given FDA Approval to Market CAP24 Paddle Lead to US Neurosurgeons
Saluda Medical wins FDA approval for CAP24 paddle lead, expanding US SCS market; phased year-end launch to drive Evoke closed-loop growth.
Clarity Pharmaceuticals to Showcase SAR-bisPSMA Prostate Cancer Data at EANM Conference
Clarity Pharma 64Cu/67Cu SAR-bisPSMA data accepted for EANM, featuring oral presentation and a 700–800-patient dataset that could reshape prostate cancer care.
Visionflex Wins A$0.8m NSW Health Hardware Contract
Visionflex (ASX:VFX) wins A$0.8m NSW Health RPM hardware contract, signaling near-term revenue visibility as it pivots to recurring software revenue.
Racura Oncology Treats First Patient in Harness-1 EGFRm Lung Cancer Trial
Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.